Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma
The purpose of this study is to test any good and bad effects of activity pevonedistat taken alone, and also to test the safety of pevonedistat in combination with standard chemotherapy, pemetrexed/cisplatin.
Mesothelioma
DRUG: pevonedistat|DRUG: Pemetrexed and cisplatin
Number of Patients Who Have a Clinical Benefit Rate (CBR) (Cohort 1), The CBR is defined as the proportion of patients CR, PR or SD at 18 weeks based on RECIST criteria., at 18 weeks post initiation of treatment|Maximum Tolerated Dose (MTD) (Cohort 2), If none of the initial cohort of 3 has a dose-limited toxicity the dose level will be escalated. If one has a DLT that dose level will be expanded with 3 more patients. Dose escalation will stop if â‰¥2 DLTs are seen at a dose level. The MTD is defined as the highest dose level at which no more than 1 of the 6 patients at that level has a DLT. If no patient in the 3-patient cohort has a DLT and the dose level is under final consideration of the MTD, an additional three patients will be treated at that level for confirmation., 3 year
The purpose of this study is to test any good and bad effects of activity pevonedistat taken alone, and also to test the safety of pevonedistat in combination with standard chemotherapy, pemetrexed/cisplatin.